Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures - Homepage
Triathlon Medical Ventures - Team
Triathlon Medical Ventures - Investment Focus
Triathlon Medical Ventures - Investment Strategy
Triathlon Medical Ventures - Investment Criteria
Contact Triathlon Medical Ventures - Evaluation Process
Triathlon Medical Ventures - Portfolio
Triathlon Medical Ventures - News
Triathlon Medical Ventures - Links
Contact Contact Triathlon Medical Ventures

Triathlon Medical Ventures

 

 

 

 


 

NEWS ARCHIVES (VIEW CURRENT NEWS)

July 16, 2012
Juventas Therapeutics Raises $22.2 Million Series B Financing (Link)

July 9, 2012
Peter Meldrum Joins the Endocyte Board of Directors (PDF)

May 30, 2012
Wound healing startup SironRX hires new CEO, gets OK on clinical trial (Link)

May 16, 2012
Mitralign Raises $35 Million Series D Financing (Link)

April 16, 2012
Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) (PDF)

March 20, 2012
Aerpio Announces Positive Phase 1 Data on First-in-class Tie2 Activator, AKB-9778, in Development for Diabetic Macular Edema (PDF)

January 9, 2012
New Company, Aerpio Therapeutics, Created to Advance Novel Tie-2 Activators and HIF-1a Stabilizers for Multiple Diseases (PDF)

August 15, 2011
Wound therapy company SironRX closes $3.4M series A investment (Link)

May 3, 2011
Akebia Therapeutics, Inc. Announces Successful Completion of Single Ascending Dose Phase 2A Pilot Study of AKB-6548 For Anemia


April 26, 2011
Akebia Therapeutics, Inc. Completes $22M Series B Financing


April 26, 2011
Endocyte Announces Intent to Seek Conditional Marketing Authorization in the European Union for Targeted Therapeutic EC145 and Companion Imaging Diagnostic EC20 for Platinum-Resistant Ovarian Cancer


April 26, 2011
Juventas Therapeutics Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure


February 9, 2011
Endocyte Announces Closing of Initial Public Offering and Over-allotment Option


January 24, 2011
Amgen to Acquire BioVex, A Privately Held Biotechnology Company Headquartered In Woburn, Mass


January 3, 2011
Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia


August 30, 2010
Endocyte Secures $15 Million Credit Facility


August 17, 2010
Endocyte Files Registration Statement with SEC for Initial Public Offering


August 2, 2010
BioVex Announces Publication of Head and Neck Cancer Clinical Trial Results with OncoVEXGM-CSF in the Journal Clinical Cancer Research


July 22, 2010
BioVex Appoints Ex Roche Oncology Head, Kapil Dhingra, to the Board of Directors


July 1, 2010
BioVex Appoints Steven Kelly as Chief Commercial Officer


June 22, 2010
Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 Diabetes Mellitus


June 9, 2010
CoLucid Pharmaceuticals, Inc. Announces Study Data Documenting Oral Efficacy of Lasmiditan (COL-144), a Selective 5-HT1F Receptor Agonist, in the Treatment of Acute Migraine Attacks


June 1, 2010
Akebia Announces Positive Results for AKB-6548 Phase 1b Clinical Study and Completes $5M Second Tranche to Series A Financing


April 6, 2010
Tolera Therapeutics Honored as One of the 2010 "Michigan 50 Companies to Watch"


April 5, 2010
Juventas Therapeutics Enrolling Phase I Clinical Trial of JVS-100 for Patients with Heart Failure


March 4, 2010
BioVex Initiates Phase 1 Clinical Trial with its Genital Herpes Vaccine, ImmunoVEXHSV2


March 3, 2010
Endocyte Announces DSMB Supports Continuation of Phase 2 PRECEDENT Study


February 3, 2010
Triathlon Medical Ventures and Affinity Capital Announce Collaboration in the Formation of the Minnesota Life Sciences Seed Fund


January 2010
MIST Therapy® The Haiti Health Care Crisis


November 10, 2009
BioVex completes $70 million financing to conclude pivotal study with its pioneering cancer treatment, OncoVEXGM-CSF (External Link)


November 3, 2009
Tolera Therapeutics Files IND Application for TOL101, Appoints O’Toole to Lead Clinical Operations


October 22, 2009
Endocyte Unveils Data on Ovarian Cancer Treatment (External Link)


October 15, 2009
Endocyte Announces Close of $26 Million Equity Financing


September 15, 2009
Akebia Announces Initiation of Phase 1 Clinical Study of AKB-6548


September 15, 2009
BioVEX Agrees SPA with the FDA for a Pivotal Phase III Study with OncoVEXGM-CSF in Head and Neck Cancer (External Link)


August 31, 2009
Akebia Appoints Victor Dzau, M.D. to Board of Directors


August 26, 2009
Endocyte Announces Achievement of Second Milestone in Collaboration with Bristol-Myers Squibb


July 28, 2009
Akebia Completes $16M Expansion of Series A Financing


July 1, 2009
Celleration Appoints Mark T. Wagner President and Chief Executive Officer (External Link)


April 7, 2009
Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug


October 31, 2008
Mitralign® Initiates it's First European Study


October 31, 2008
Symphony Drums Up $10M On Way To Series C


October 28, 2008
CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development


October 10, 2008
AcelleRX Therapeutics Raises $6.9 Million From Investors


September 3, 2008
Triathlon Medical Ventures Adds New Company to Portfolio — Expanding Orthopedics, Inc. Offers Broad Platform of Cutting-edge Technology


July 11, 2008
CoLucid Tries to Prove That a Virtual Biotech Can Produce Real Returns

July 1, 2008
CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound

June 6, 2008
Tolera Therapeutics Closes Series A Financing, Raises $8 Million to Begin Antibody Manufacturing and Working With FDA on Clinical Trials


April 22, 2008
FDA Agrees to First SPA for an Oncolytic Product


February 15, 2008
Symphony Medical thinks it can tackle large cardiology markets with its seemingly simple approach to alter troubled hearts

February 8, 2008
Triathlon Invests In Cancer Firm

November 29, 2007
Renal Solutions, Inc. Announces Acquisition by Fresenius Medical Care

September 21, 2007
Pradama Pharmaceutial Firms Gets Second-Round Funding


September 20, 2007
BioVex Appoints Dr. Leonard Post to Board of Directors

August 27, 2007
P&G Job Got Foot in the Door


July 17, 2007
The Picture of Success: HydroCision Inc.


July 9, 2007
BioVex Raises $22 Million in First Close of Series E Financing

June 25, 2007
Boston Scientific Announces Agreement to Acquires Remon Medical Technlogies, Inc.


March 23 , 2007
Endocyte Secures $15 Million in Series C-3 Round of Financing


February 13, 2007
CS-Keys in Forefront of Fight Against Cancer

January 2 , 2007
BioCrossroads CEO: Help Life Sciences Grow

December 21, 2006
Firm Develops High-Tech Medical Tool... Device Useful for Back Surgery

December 19, 2006
VC Brings Investment Muscle to Hoosier Life-Sciences Startups

December 11, 2006
HydroCision Announces $12.7 Million Venture Financing ... Dennis B. Costello, Managing Partner, Triathlon Medical Ventures, Joins HydroCision's Board of Directors

November 7, 2006
Mitralign Shines at TCT 2006; Performs Live Case & Reveals Clinical Strategy

October 9, 2006
Michael A. Sherman Joins Endocyte as CFO


October 6, 2006
Remon Medical Announces First European Implants of the Remon ImPressureTM, A Wireless Device for Monitoring Pulmonary Artery Pressure in Congestive Heart Failure Patients


July 18, 2006
Renal Solutions Announces Medical Advisory Board

July 17, 2006
A Company Formed by Indiana University Researchers has Received a Significant Seed Investment from Triathlon Medical Ventures


June 27, 2006
Renal Solutions Announces Addition to Board of Directors


June 8, 2006
Renal Solutions Announces FDA 501(k) Clearance of the Allient Sorbent Hemodialysis System for Chronic and Acute Hemodialysis


May 2, 2006
Cincinnati VC Firm Triathlon Adds $9M to Fund, Closes at $105M

April 27, 2006
Ohio PERS Keeps Money at Home - Retirement System Invests $27 Million in Local Firms

April 20, 2006
Endocyte Begins Phase 1 Trial of EC145 for Treatment of Refractory Solid Tumors

April 20, 2006
Mitralign Announces New Investment by Triathlon Medical Ventures


February 28, 2006
Cleveland Clinic Spin-Off Raises $6 Million to Develop Treatments for Atrial Fibrillation

January 17, 2006
CoLucid Pharmaceuticals Announces $16.5 Million Series A Financing

January 5, 2006
Endocyte Signs Agreement with Bristol-Myers Squibb to Develop and Commercialize Folate-Targeted Chemotherapeutic Agents

November 15, 2005
Kereos' Collaborators Present on Targeted Therapies for Cardiovascular Disease

November 1, 2005
Celleratio
n® Receives $20.6 Million in Series C Funding

July 11, 2005
$10 Million Seed Fund About to Take Off - Venture Fund Will Invest in Early - Stage Life Sciences Companies Across the State


June 22, 2005
Renal Solutions, Inc. Announces FDA 510(k) Clearance of the Allient® Sorbent Hemodialysis System for Chronic and Acute Hemodialysis


March 8, 2005
Renal Solutions, Inc. Completes $16.5 Million Series B Financing and Will Present at the SG Cowen Health Care Conference

January 4, 2005
SutureTek Closes its B Series Financing


December 27, 2004
Remon Medical Technologies Ltd. Completes Series C Financing, Raising $26 Million

December 6, 2004
Endocyte Secures Close to $23 Million in Series C-2 Round of Financing

October 5, 2004
Indiana Future Fund Invests in Triathlon Medical Ventures Fund

October 4, 2004
Triathlon Lands $96M in Venture Funding


BACK TO TOP

 
 
Copyright © 2004 - Triathlon Medical Ventures - All Rights Reserved Web Site Credits Legal Notices & Privacy Policy